Skip to main content
PMC home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1994 Feb;78(2):120–124. doi: 10.1136/bjo.78.2.120

High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS.

M Diaz-Llopis 1, E España 1, G Muñoz 1, A Navea 1, E Chipont 1, J Cano 1, J L Menezo 1, F J Romero 1
PMCID: PMC504713  PMID: 8123619

Abstract

The efficacy and tolerance of high dose intravitreal foscarnet for cytomegalovirus retinitis in patients with AIDS was studied. Foscarnet in a dose of 2400 micrograms was injected directly into the vitreous of 11 patients (15 eyes). Five patients had active retinitis (eight eyes, 53.3%), and received a 3 week induction therapy of six injections as the first step. Six patients had initial inactive retinitis (seven eyes, 46.7%), and received only maintenance therapy which consisted of a weekly injection. The main indications for intravitreal therapy were: myelosuppression, kidney toxicity, catheter related sepsis, or refusal of intravenous therapy. The patients were followed for a mean period of 16 weeks (range 8-28 weeks) and received a total of 304 injections. Vitreous foscarnet levels were measured by high performance liquid chromatography. After a 3 week course of induction therapy, complete resolution of the active retinitis was seen in 62.5% (5/8 cases), while 37.5% (3/8 cases) had partial resolution. No cases failed to respond or progress. The rate of relapse on maintenance therapy was 33% (five of 15 eyes) by 20 weeks, and two of these eyes did not respond to reinduction and progressed in involvement of the macula or optic nerve. Neither important local complications nor intraocular drug toxicity were observed. Vitreous foscarnet levels in two different patients were 896 mumol/l and 74.9 mumol/l at 22 3/4 hours and 42 1/2 hours after the injection. Intravitreal foscarnet appears to be a safe, effective, and useful alternative in patients with intolerance to intravenous and viral therapy.

Full text

PDF
120

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cantrill H. L., Henry K., Melroe N. H., Knobloch W. H., Ramsay R. C., Balfour H. H., Jr Treatment of cytomegalovirus retinitis with intravitreal ganciclovir. Long-term results. Ophthalmology. 1989 Mar;96(3):367–374. doi: 10.1016/s0161-6420(89)32900-9. [DOI] [PubMed] [Google Scholar]
  2. Chrisp P., Clissold S. P. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs. 1991 Jan;41(1):104–129. doi: 10.2165/00003495-199141010-00009. [DOI] [PubMed] [Google Scholar]
  3. Cochereau-Massin I., Lehoang P., Lautier-Frau M., Zazoun L., Marcel P., Robinet M., Matheron S., Katlama C., Gharakhanian S., Rozenbaum W. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology. 1991 Sep;98(9):1348–1355. doi: 10.1016/s0161-6420(91)32135-3. [DOI] [PubMed] [Google Scholar]
  4. Drew W. L., Miner R. C., Busch D. F., Follansbee S. E., Gullett J., Mehalko S. G., Gordon S. M., Owen W. F., Jr, Matthews T. R., Buhles W. C. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis. 1991 Apr;163(4):716–719. doi: 10.1093/infdis/163.4.716. [DOI] [PubMed] [Google Scholar]
  5. Díaz-Llopis M., Chipont E., Sanchez S., España E., Navea A., Menezo J. L. Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome. Am J Ophthalmol. 1992 Dec 15;114(6):742–747. doi: 10.1016/s0002-9394(14)74054-1. [DOI] [PubMed] [Google Scholar]
  6. Fanning M. M., Read S. E., Benson M., Vas S., Rachlis A., Kozousek V., Mortimer C., Harvey P., Schwartz C., Chew E. Foscarnet therapy of cytomegalovirus retinitis in AIDS. J Acquir Immune Defic Syndr. 1990;3(5):472–479. [PubMed] [Google Scholar]
  7. Freeman W. R., Lerner C. W., Mines J. A., Lash R. S., Nadel A. J., Starr M. B., Tapper M. L. A prospective study of the ophthalmologic findings in the acquired immune deficiency syndrome. Am J Ophthalmol. 1984 Feb;97(2):133–142. doi: 10.1016/s0002-9394(14)76082-9. [DOI] [PubMed] [Google Scholar]
  8. Friedman A. H. The retinal lesions of the acquired immune deficiency syndrome. Trans Am Ophthalmol Soc. 1984;82:447–491. [PMC free article] [PubMed] [Google Scholar]
  9. Gross J. G., Bozzette S. A., Mathews W. C., Spector S. A., Abramson I. S., McCutchan J. A., Mendez T., Munguia D., Freeman W. R. Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology. 1990 May;97(5):681–686. doi: 10.1016/s0161-6420(90)32552-6. [DOI] [PubMed] [Google Scholar]
  10. Hassanzadeh M. K., Aweeka F. T., Wu S., Jacobson M. A., Gambertoglio J. G. Determination of phosphonoformic acid in human plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1990 Jan 26;525(1):133–140. doi: 10.1016/s0378-4347(00)83386-1. [DOI] [PubMed] [Google Scholar]
  11. Heinemann M. H. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Arch Ophthalmol. 1989 Dec;107(12):1767–1772. doi: 10.1001/archopht.1989.01070020849025. [DOI] [PubMed] [Google Scholar]
  12. Henderly D. E., Freeman W. R., Causey D. M., Rao N. A. Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology. 1987 Apr;94(4):425–434. doi: 10.1016/s0161-6420(87)33454-2. [DOI] [PubMed] [Google Scholar]
  13. Henry K., Cantrill H., Fletcher C., Chinnock B. J., Balfour H. H., Jr Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol. 1987 Jan 15;103(1):17–23. doi: 10.1016/s0002-9394(14)74163-7. [DOI] [PubMed] [Google Scholar]
  14. Holland G. N., Buhles W. C., Jr, Mastre B., Kaplan H. J. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy. Study Group. Arch Ophthalmol. 1989 Dec;107(12):1759–1766. doi: 10.1001/archopht.1989.01070020841024. [DOI] [PubMed] [Google Scholar]
  15. Holland G. N., Pepose J. S., Pettit T. H., Gottlieb M. S., Yee R. D., Foos R. Y. Acquired immune deficiency syndrome. Ocular manifestations. Ophthalmology. 1983 Aug;90(8):859–873. doi: 10.1016/s0161-6420(83)80009-8. [DOI] [PubMed] [Google Scholar]
  16. Holland G. N., Sakamoto M. J., Hardy D., Sidikaro Y., Kreiger A. E., Frenkel L. M. Treatment of cytomegalovirus retinopathy in patients with acquired immunodeficiency syndrome. Use of the experimental drug 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine. Arch Ophthalmol. 1986 Dec;104(12):1794–1800. doi: 10.1001/archopht.1986.01050240068042. [DOI] [PubMed] [Google Scholar]
  17. Holland G. N., Sidikaro Y., Kreiger A. E., Hardy D., Sakamoto M. J., Frenkel L. M., Winston D. J., Gottlieb M. S., Bryson Y. J., Champlin R. E. Treatment of cytomegalovirus retinopathy with ganciclovir. Ophthalmology. 1987 Jul;94(7):815–823. doi: 10.1016/s0161-6420(87)33534-1. [DOI] [PubMed] [Google Scholar]
  18. Holland G. N., Sison R. F., Jatulis D. E., Haslop M. G., Sakamoto M. J., Wheeler N. C. Survival of patients with the acquired immune deficiency syndrome after development of cytomegalovirus retinopathy. UCLA CMV Retinopathy Study Group. Ophthalmology. 1990 Feb;97(2):204–211. doi: 10.1016/s0161-6420(90)32616-7. [DOI] [PubMed] [Google Scholar]
  19. Jabs D. A., Newman C., De Bustros S., Polk B. F. Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology. 1987 Jul;94(7):824–830. doi: 10.1016/s0161-6420(87)33535-3. [DOI] [PubMed] [Google Scholar]
  20. Jabs D. A. Treatment of cytomegalovirus retinitis--1992. Arch Ophthalmol. 1992 Feb;110(2):185–187. doi: 10.1001/archopht.1992.01080140041022. [DOI] [PubMed] [Google Scholar]
  21. Jacobson M. A., Drew W. L., Feinberg J., O'Donnell J. J., Whitmore P. V., Miner R. D., Parenti D. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. J Infect Dis. 1991 Jun;163(6):1348–1351. doi: 10.1093/infdis/163.6.1348. [DOI] [PubMed] [Google Scholar]
  22. Jacobson M. A., O'Donnell J. J., Mills J. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrob Agents Chemother. 1989 May;33(5):736–741. doi: 10.1128/aac.33.5.736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Lehoang P., Girard B., Robinet M., Marcel P., Zazoun L., Matheron S., Rozenbaum W., Katlama C., Morer I., Lernestedt J. O. Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology. 1989 Jun;96(6):865–874. doi: 10.1016/s0161-6420(89)32824-7. [DOI] [PubMed] [Google Scholar]
  24. Palestine A. G., Rodrigues M. M., Macher A. M., Chan C. C., Lane H. C., Fauci A. S., Masur H., Longo D., Reichert C. M., Steis R. Ophthalmic involvement in acquired immunodeficiency syndrome. Ophthalmology. 1984 Sep;91(9):1092–1099. doi: 10.1016/s0161-6420(84)34201-4. [DOI] [PubMed] [Google Scholar]
  25. Palestine A. G., Stevens G., Jr, Lane H. C., Masur H., Fujikawa L. S., Nussenblatt R. B., Rook A. H., Manischewitz J., Baird B., Megill M. Treatment of cytomegalovirus retinitis with dihydroxy propoxymethyl guanine. Am J Ophthalmol. 1986 Jan 15;101(1):95–101. doi: 10.1016/0002-9394(86)90470-8. [DOI] [PubMed] [Google Scholar]
  26. Pepose J. S., Holland G. N., Nestor M. S., Cochran A. J., Foos R. Y. Acquired immune deficiency syndrome. Pathogenic mechanisms of ocular disease. Ophthalmology. 1985 Apr;92(4):472–484. doi: 10.1016/s0161-6420(85)34008-3. [DOI] [PubMed] [Google Scholar]
  27. Rosecan L. R., Stahl-Bayliss C. M., Kalman C. M., Laskin O. L. Antiviral therapy for cytomegalovirus retinitis in AIDS with dihydroxy propoxymethyl guanine. Am J Ophthalmol. 1986 Apr 15;101(4):405–418. doi: 10.1016/0002-9394(86)90638-0. [DOI] [PubMed] [Google Scholar]
  28. Sanborn G. E., Anand R., Torti R. E., Nightingale S. D., Cal S. X., Yates B., Ashton P., Smith T. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device. Arch Ophthalmol. 1992 Feb;110(2):188–195. doi: 10.1001/archopht.1992.01080140044023. [DOI] [PubMed] [Google Scholar]
  29. She S. C., Peyman G. A., Schulman J. A. Toxicity of intravitreal injection of foscarnet in the rabbit eye. Int Ophthalmol. 1988;12(2):151–154. doi: 10.1007/BF00137142. [DOI] [PubMed] [Google Scholar]
  30. Ussery F. M., 3rd, Gibson S. R., Conklin R. H., Piot D. F., Stool E. W., Conklin A. J. Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis. Ophthalmology. 1988 May;95(5):640–648. doi: 10.1016/s0161-6420(88)33147-7. [DOI] [PubMed] [Google Scholar]
  31. Wahren B., Oberg B. Reversible inhibition of cytomegalovirus replication by phosphonoformate. Intervirology. 1980;14(1):7–15. doi: 10.1159/000149156. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES